Microfluidic Technology Creates Uniform Microspheres for Month-Long Leuprolide Release
Researchers used microfluidic technology to create uniform PLGA microspheres that released the peptide drug leuprolide steadily for about 28 days.
Quick Facts
What This Study Found
Using a glass capillary microfluidic device, researchers produced monodisperse PLGA microspheres with a uniform particle size of 80 μm and a distinct core-shell structure for leuprolide acetate delivery. At an optimal gelatin concentration of 7.5 mg/mL in the inner aqueous phase, microspheres achieved maximum encapsulation efficiency of 80.28% and drug loading of 4.24%.
The microspheres sustained leuprolide release for approximately 28 days in vitro. Drug loading increased proportionally with leuprolide concentration in the inner phase. Gelatin incorporation and collecting solution pH were identified as the critical factors controlling encapsulation efficiency.
Key Numbers
How They Did This
Researchers developed a glass capillary microfluidic device to generate water-in-oil-in-water (W/O/W) emulsions that solidified into PLGA microspheres. They systematically varied gelatin concentration in the internal aqueous phase, collecting solution composition, and leuprolide concentration to optimize encapsulation. Microsphere morphology was characterized for size uniformity and core-shell structure. In vitro drug release was measured over 28 days.
Why This Research Matters
Current leuprolide microsphere products (like Lupron Depot) are made using conventional emulsification techniques that produce particles of varying sizes, which can lead to inconsistent drug release. Microfluidic manufacturing creates extremely uniform particles, potentially improving the predictability and consistency of drug delivery. This technology could be applied to many other peptide and protein drugs that need sustained release, advancing the field of injectable depot formulations.
The Bigger Picture
Microsphere-based drug delivery is a mature but still improving field. The shift from batch emulsification to microfluidic production represents a manufacturing evolution that could yield more consistent, higher-quality products. For peptide drugs specifically — which are expensive and often require precise dosing — uniform microspheres could reduce waste, improve pharmacokinetics, and potentially reduce the frequency of injections. This study demonstrates a platform technology applicable beyond leuprolide to any water-soluble peptide or protein drug.
What This Study Doesn't Tell Us
This is an in vitro study only — no animal testing was performed to confirm that the 28-day release profile translates to sustained drug levels in vivo. Microfluidic production rates are typically much slower than conventional methods, which could limit commercial scalability. The 80 μm particle size is relatively large for injection, and injectability was not assessed. Comparison with commercially available leuprolide microsphere products was not included.
Questions This Raises
- ?Does the in vitro 28-day release profile translate to sustained therapeutic leuprolide levels in animal models?
- ?Can microfluidic production be scaled up to commercially viable throughput for microsphere manufacturing?
- ?How do these uniform microspheres compare to commercial Lupron Depot in terms of pharmacokinetics and bioavailability?
Trust & Context
- Key Stat:
- 80.28% encapsulation Maximum encapsulation efficiency for leuprolide in PLGA microspheres produced by microfluidic technology
- Evidence Grade:
- This is a materials science/pharmaceutical engineering study demonstrating proof of concept for a manufacturing technique. It provides strong in vitro data for the formulation approach but lacks in vivo validation.
- Study Age:
- Published in 2025, this is a very recent study reflecting the current state of microfluidic drug delivery technology.
- Original Title:
- Microfluidic Regulation of Core-Shell PLGA Microspheres for Sustained Release of Leuprolide Acetate.
- Published In:
- Langmuir : the ACS journal of surfaces and colloids, 41(27), 17893-17901 (2025)
- Authors:
- Wei, Ruoxin, Dou, Jiaze, Wu, Yihui, Li, Jinjin, Cen, Lian, Xi, Zhenhao
- Database ID:
- RPEP-14108
Evidence Hierarchy
Frequently Asked Questions
What are microspheres and why are they used for peptide drugs?
Microspheres are tiny biodegradable spheres (about the width of a human hair) that encapsulate drugs inside a polymer shell. As the polymer slowly dissolves, it releases the drug over weeks to months. This is ideal for peptide drugs like leuprolide, which would otherwise be broken down in the body within hours and require daily injections. Instead, a single microsphere injection can maintain drug levels for a month.
How does microfluidic production differ from conventional methods?
Conventional methods mix large batches of ingredients together, producing microspheres of many different sizes. Microfluidic production uses precision channels to form one droplet at a time, creating particles that are almost identical in size and structure. This uniformity means every microsphere releases its drug at the same rate, making the overall drug delivery more predictable and consistent.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14108APA
Wei, Ruoxin; Dou, Jiaze; Wu, Yihui; Li, Jinjin; Cen, Lian; Xi, Zhenhao. (2025). Microfluidic Regulation of Core-Shell PLGA Microspheres for Sustained Release of Leuprolide Acetate.. Langmuir : the ACS journal of surfaces and colloids, 41(27), 17893-17901. https://doi.org/10.1021/acs.langmuir.5c01667
MLA
Wei, Ruoxin, et al. "Microfluidic Regulation of Core-Shell PLGA Microspheres for Sustained Release of Leuprolide Acetate.." Langmuir : the ACS journal of surfaces and colloids, 2025. https://doi.org/10.1021/acs.langmuir.5c01667
RethinkPeptides
RethinkPeptides Research Database. "Microfluidic Regulation of Core-Shell PLGA Microspheres for ..." RPEP-14108. Retrieved from https://rethinkpeptides.com/research/wei-2025-microfluidic-regulation-of-coreshell
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.